Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Penumbra, Inc. Reports First Quarter 2024 Financial Results

      Penumbra, Inc. Logo (PRNewsFoto/Penumbra, Inc.)

      News provided by

      Penumbra, Inc.

      May 07, 2024, 16:05 ET

      Share this article

      Share this article


      ALAMEDA, Calif., May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024.

      • Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency1, compared to the first quarter of 2023.
      • U.S. thrombectomy revenue of $150.3 million in the first quarter of 2024 increased 35.2% compared to the first quarter of 2023.
      • Non-GAAP income from operations1 of $19.3 million in the first quarter of 2024.
      • Adjusted EBITDA1 of $37.6 million and adjusted EBITDA margin of 13.5% in the first quarter of 2024.
      • Cash and marketable investments increased $24.3 million in the first quarter of 2024 compared to the fourth quarter of 2023 driven by an increase in profitability and improvements in working capital.
      • Strong growth trends in the first quarter reinforce our total revenue and U.S. thrombectomy revenue guidance ranges of 16-20% and 27-30%, respectively, for full year 2024.

      First Quarter 2024 Financial Results
      Total revenue increased to $278.7 million for the first quarter of 2024 compared to $241.4 million for the first quarter of 2023, an increase of 15.4%, or 15.2% in constant currency1. The United States represented 75.2% of total revenue and international represented 24.8% of total revenue for the first quarter of 2024. Revenue from the U.S. increased 22.0% while revenue from our international regions decreased 0.7%, or 1.7% in constant currency1. Revenue from sales of our global thrombectomy products grew to $187.7 million in the first quarter of 2024, an increase of 29.5%, or 29.3% in constant currency1 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 35.2% over the same period a year ago. Revenue from sales of our global embolization and access products declined to $91.0 million for the first quarter of 2024, a decrease of 5.7%, or 6.0% in constant currency1 from the same period a year ago, driven primarily by our international embolization and access products which decreased by 11.6% over the same period a year ago.

      Gross profit for the first quarter of 2024 was $181.1 million, or 65.0% of total revenue compared to $151.1 million, or 62.6% of total revenue, for the first quarter of 2023. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.

      Total operating expenses, including a $2.4 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition for both periods and $4.8 million in non-recurring litigation related expenses for the first quarter of 2024, were $169.0 million, or 60.7% of total revenue for the first quarter of 2024, and $143.1 million, or 59.3% of total revenue, for the first quarter of 2023. Excluding the charges noted above, total non-GAAP operating expenses1 were $161.8 million, or 58.1% of total revenue, for the first quarter of 2024, and $140.7 million, or 58.3% of total revenue for the first quarter of 2023, respectively. R&D expenses were $24.6 million for the first quarter of 2024, compared to $20.0 million for the first quarter of 2023. SG&A expenses were $144.4 million for the first quarter of 2024, compared to $123.1 million for the first quarter of 2023.

      Income from operations was $12.1 million for the first quarter of 2024, compared to income from operations of $8.0 million for the first quarter of 2023. Excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition of $2.4 million for both periods and $4.8 million in non-recurring litigation related expenses for the first quarter of 2024, non-GAAP income from operations1 was $19.3 million for the first quarter of 2024 compared to non-GAAP income from operations of $10.4 million for the first quarter of 2023.

      Full Year 2024 Financial Outlook
      The Company reiterates guidance for total revenue for 2024 to be in the range of $1,230.0 million to $1,270.0 million, representing year over year growth of 16% to 20% compared to 2023 revenue of $1,058.5 million. The Company also continues to project the U.S. thrombectomy franchise will grow 27% to 30% year-over-year, primarily driven by its Computer-Assisted Vacuum Thrombectomy ("CAVT") products. The Company also continues to expect gross margin expansion in the range of 100 to 150 basis points and total non-GAAP operating margin expansion in the range of 100 to 200 basis points in 2024 compared to full year 2023.

      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

      Webcast and Conference Call Information
      Penumbra, Inc. will host a conference call to discuss the first quarter 2024 financial results after market close on Tuesday, May 7, 2024 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 596-4144 for domestic and international callers (conference id: 7567226), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.

      About Penumbra
      Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.

      Non-GAAP Financial Measures
      In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency, b) non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share ("EPS") and c) adjusted EBITDA.

      Constant Currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.

      Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:

      • the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives;
      • the excess tax benefits associated with share-based compensation arrangements; and
      • non-recurring litigation related expenses.

      Adjusted EBITDA. The Company's adjusted EBITDA reflects the exclusion from GAAP net income of:

      • non-cash operating charges such as stock-based compensation and depreciation and amortization;
      • non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes; and
      • non-recurring litigation related expenses.

      Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.

      Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, and expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees. Further, we consider adjusted EBITDA a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation and depreciation and amortization, non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes and non-recurring litigation related expenses.

      The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.

      Forward-Looking Statements
      Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 22, 2024. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

      Penumbra, Inc.

      Condensed Consolidated Balance Sheets

      (unaudited)

      (in thousands)




      March 31, 2024


      December 31, 2023

      Assets





      Current assets:





           Cash and cash equivalents


      $                  223,114


      $                  167,486

           Marketable investments


      90,360


      121,701

           Accounts receivable, net


      191,989


      201,768

           Inventories


      398,366


      388,023

           Prepaid expenses and other current assets


      31,194


      36,424

                Total current assets


      935,023


      915,402

      Property and equipment, net


      75,744


      72,691

      Operating lease right-of-use assets


      185,845


      188,756

      Finance lease right-of-use assets


      30,234


      31,092

      Intangible assets, net


      68,421


      71,056

      Goodwill


      166,103


      166,270

      Deferred taxes


      84,661


      85,158

      Other non-current assets


      33,814


      25,880

               Total assets


      $               1,579,845


      $               1,556,305

      Liabilities and Stockholders' Equity





      Current liabilities:





           Accounts payable


      $                    32,454


      $                    27,155

           Accrued liabilities


      106,549


      110,555

        Current operating lease liabilities


      11,520


      11,203

        Current finance lease liabilities


      2,280


      2,231

                Total current liabilities


      152,803


      151,144

      Non-current operating lease liabilities


      194,537


      197,229

      Non-current finance lease liabilities


      23,098


      23,680

      Other non-current liabilities


      5,876


      5,308

                Total liabilities


      376,314


      377,361

      Stockholders' equity:





      Common stock


      39


      39

      Additional paid-in capital


      1,062,470


      1,047,198

      Accumulated other comprehensive loss


      (4,838)


      (3,151)

      Retained earnings


      145,860


      134,858

      Total stockholders' equity


      1,203,531


      1,178,944

      Total liabilities and stockholders' equity


      $               1,579,845


      $               1,556,305

      Penumbra, Inc.

      Condensed Consolidated Statements of Operations

      (unaudited)

      (in thousands, except share and per share amounts)




      Three Months Ended March 31,



      2024


      2023

      Revenue


      $                  278,655


      $                  241,398

      Cost of revenue


      97,516


      90,326

      Gross profit


      181,139


      151,072

      Operating expenses:





      Research and development


      24,626


      19,986

      Sales, general and administrative


      144,412


      123,078

      Total operating expenses


      169,038


      143,064

      Income from operations


      12,101


      8,008

      Interest and other income, net


      2,525


      644

      Income before income taxes


      14,626


      8,652

      Provision for income taxes


      3,624


      90

      Net income


      $                    11,002


      $                      8,562






      Net income per share:





      Basic


      $                         0.28


      $                         0.22

      Diluted


      $                         0.28


      $                         0.22

      Weighted average shares outstanding:





      Basic


      38,717,334


      38,186,342

      Diluted


      39,387,359


      39,075,388

      Penumbra, Inc.

      Reconciliation of GAAP Operating Expenses and GAAP Income from Operations to Non-GAAP Operating Expenses and Non-GAAP
      Income from Operations1

      (unaudited)

      (in thousands)




      Three Months Ended March 31,



      2024


      2023

      GAAP operating expenses


      $            169,038


      $            143,064

      GAAP operating expenses includes the effect of the following items:





      Non-recurring litigation related expenses


      4,823


      —

      Amortization of finite lived intangible assets acquired


      2,380


      2,380

      Non-GAAP operating expenses


      $            161,835


      $            140,684






      GAAP income from operations


      $              12,101


      $                8,008

      GAAP income from operations includes the effect of the following items:





      Non-recurring litigation related expenses


      4,823


      —

      Amortization of finite lived intangible assets acquired


      2,380


      2,380

      Non-GAAP income from operations


      $              19,304


      $              10,388






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

      Penumbra, Inc.

      Reconciliation of GAAP Net Income and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1

      (unaudited)

      (in thousands, except share and per share amounts)




      Three Months Ended

      March 31, 2024


      Three Months Ended

      March 31, 2023



      Net income


      Diluted EPS


      Net income


      Diluted EPS

      GAAP net income


      $             11,002


      $                 0.28


      $               8,562


      $                0.22

      GAAP net income includes the effect of the following items:









      Non-recurring litigation related expenses


      4,823


      0.12


      —


      —

      Amortization of finite lived intangible assets acquired


      2,380


      0.06


      2,380


      0.06

      Tax effect on the non-GAAP adjustments above2


      (1,736)


      (0.04)


      (558)


      (0.01)

      Excess tax benefits related to stock compensation awards


      (287)


      (0.01)


      (1,440)


      (0.04)

      Non-GAAP net income


      $             16,182


      $                 0.41


      $               8,944


      $                0.23










      GAAP diluted EPS




      $                 0.28




      $                0.22

      Non-GAAP diluted EPS




      $                 0.41




      $                0.23










      Weighted average shares outstanding used to compute:









      GAAP diluted EPS


      39,387,359


      39,075,388

      Non-GAAP diluted EPS


      39,387,359


      39,075,388






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. 

      2For the three months ended March 31, 2024 and 2023, management used a combined federal and state tax rate of 24.10% and 23.44%, respectively, to compute the tax effect of non-GAAP adjustments.

      Penumbra, Inc.

      Reconciliation of GAAP Net Income to Adjusted EBITDA and Adjusted EBITDA Margin1

      (unaudited)

      (in thousands, except for percentages)




      Three Months Ended March 31,



      2024


      2023

      GAAP net income


      $          11,002


      $             8,562

      Adjustments to GAAP net income:





      Depreciation and amortization expense


      7,519


      6,575

      Interest income, net


      (2,891)


      (554)

      Provision for income taxes


      3,624


      90

      Stock-based compensation expense


      13,569


      12,766

      Non-recurring litigation related expenses


      4,823


      —

      Adjusted EBITDA


      $          37,646


      $          27,439






      Revenue


      $        278,655


      $        241,398

      Adjusted EBITDA


      $          37,646


      $          27,439

      Adjusted EBITDA margin


      13.5 %


      11.4 %






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. 

      Penumbra, Inc.

      Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1

      (unaudited)

      (in thousands, except for percentages)




      Three Months Ended March 31,


      Reported Change


      FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      United States


      $      209,644


      $      171,879


      $       37,765


      22.0 %


      $               —


      $       37,765


      22.0 %

      International


      69,011


      69,519


      (508)


      (0.7) %


      (640)


      (1,148)


      (1.7) %

      Total


      $      278,655


      $      241,398


      $       37,257


      15.4 %


      $           (640)


      $       36,617


      15.2 %

      Penumbra, Inc.

      Reconciliation of Revenue Change by Product Categories and Geographic Regions to Constant Currency Revenue Growth1

      (unaudited)

      (in thousands, except for percentages)




      Three Months Ended March 31,


      Reported Change


       FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      Thrombectomy


      $       187,703


      $      144,980


      $       42,723


      29.5 %


      $          (309)


      $       42,414


      29.3 %

      Embolization and Access


      90,952


      96,418


      (5,466)


      (5.7) %


      (331)


      (5,797)


      (6.0) %

      Total


      $       278,655


      $      241,398


      $       37,257


      15.4 %


      $          (640)


      $       36,617


      15.2 %




      Three Months Ended March 31,


      Reported Change


       FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      Thrombectomy















      United States


      $        150,284


      $       111,189


      $         39,095


      35.2 %


      $                —


      $         39,095


      35.2 %

      International


      37,419


      33,791


      3,628


      10.7 %


      (309)


      3,319


      9.8 %

        Total Thrombectomy


      187,703


      144,980


      42,723


      29.5 %


      (309)


      42,414


      29.3 %

      Embolization and Access















      United States


      59,360


      60,690


      (1,330)


      (2.2) %




      (1,330)


      (2.2) %

      International


      31,592


      35,728


      (4,136)


      (11.6) %


      (331)


      (4,467)


      (12.5) %

        Total Embolization and Access


      90,952


      96,418


      (5,466)


      (5.7) %


      (331)


      (5,797)


      (6.0) %

      Total


      $        278,655


      $       241,398


      $         37,257


      15.4 %


      $            (640)


      $         36,617


      15.2 %






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

      Investor Relations
      Penumbra, Inc.
      510-995-2461
      [email protected] 

      SOURCE Penumbra, Inc.

      Modal title

      Also from this source

      Penumbra, Inc. Reports Third Quarter 2026 Financial Results

      Penumbra, Inc. Reports Third Quarter 2026 Financial Results

      Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026....

      Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

      Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

      Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      Earnings Forecasts & Projections

      Earnings Forecasts & Projections

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.